Trial Profile
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT): A Single-arm Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Vemurafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms IMPROVEMENT
- 12 Jan 2022 Results (n=21 enrolled between 12th January 2018, and 18th June 2021) published in the European Journal of Cancer
- 15 Aug 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.
- 15 Aug 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.